Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer

Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer

Abstract Background Bevacizumab, a monoclonal antibody against soluble VEGFA, is an approved and commonly administered anti-angiogenic drug in patients with metastasized colorectal cancer (mCRC). The survival benefit of anti-VEGF therapy in mCRC patients is limited to a few months, and acquired resi...

Full description

Bibliographic Details
Main Authors: Qing Zhou, Samantha O. Perakis, Peter Ulz, Sumitra Mohan, Jakob M. Riedl, Emina Talakic, Sigurd Lax, Martin Tötsch, Gerald Hoefler, Thomas Bauernhofer, Martin Pichler, Armin Gerger, Jochen B. Geigl, Ellen Heitzer, Michael R. Speicher
Format: Article
Language:English
Published: BMC 2020-02-01
Series:Genome Medicine
Subjects:
Cell-free DNA
POLR1D
Bevacizumab
Whole-genome sequencing
Therapy resistance
Precision medicine
Online Access:http://link.springer.com/article/10.1186/s13073-020-0719-6

Internet

http://link.springer.com/article/10.1186/s13073-020-0719-6

Similar Items